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Both the inﬂammatory potential and cognitive function decline during aging. The association between
the repertoire of inﬂammatory biomarkers and cognitive decline is unclear. Inﬂammatory cytokines have
been reported to be increased, decreased, or unchanged in the cerebrospinal ﬂuid and sera of subjects
with dementia. We assessed 112 postmortem brains from subjects diagnosed with poststroke dementia
(PSD), vascular dementia, mixed dementia, and Alzheimer’s disease (AD), comparing those to poststroke
nondemented (PSND) subjects and age-matched controls. We analyzed 5 brain regions including the
gray and white matter from the frontal and temporal lobes for a panel of cytokine and/or chemokine
analytes using multiplex-array assays. Of the 37 analytes, 14 were under or near the detection limits, 7
were close to the lowest detection level, and 16 cytokines were within the linear range of the assay. We
observed widely variable concentrations of C-reactive protein (CRP) and serum amyloid A at the high end
(1e150 ng/mg protein), whereas several of the interleukins (IL, interferon-gamma and tumor necrosis
factor) at the low end (1e10 pg/mg). There were also regional variations; most notable being high
concentrations of some cytokines (e.g., CRP and angiogenesis panel) in the frontal white matter. Overall,
we found decreased concentrations of several cytokines, including IL-1 beta (p ¼ 0.000), IL-6 (p ¼ 0.000),
IL-7 (p ¼ 0.000), IL-8 (p ¼ 0.000), IL-16 (p ¼ 0.001), interferon-inducible proteine10 (0.044), serum
amyloid A (p ¼ 0.011), and a trend in IL-1 alpha (p ¼ 0.084) across all dementia groups compared to
nondemented controls. IL-6 and IL-8 were signiﬁcantly lower in dementia subjects than in nondemented
subjects in every region. In particular, lower levels of IL-6 and IL-8 were notable in the PSD compared to
PSND subjects. Because these 2 stroke groups had comparable degree of vascular pathology, the lower
production of IL-6 and IL-8 in PSD reafﬁrms a possible speciﬁc involvement of immunosenescence in
dementia pathogenesis. In contrast, CRP was not altered between dementia and nondementia subjects or
between PSD and PSND. Our study provides evidence not only for the feasibility of tracking cytokines in
postmortem brain tissue but also suggests differentially impaired inﬂammatory mechanisms underlying
dementia including AD. There was a diminished inﬂammatory response, possibly reﬂecting immuno-
senescence and cerebral atrophy, in all dementias. Strategies to enhance anti-inﬂammatory cytokines
and boost the immune system of the brain may be beneﬁcial for preventing cognitive dysfunction,
especially after stroke.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ience, Newcastle University,
E4 5PL, UK. Tel.: þ44 191 248
kalaria@ncl.ac.uk (R.N. Kalaria).
Inc. This is an open access article u1. Introduction
During the last decade, there has been a surge of interest in
whether inﬂammatory and immune responses contribute to
aging-related dementias. Both the inﬂammatory potential and the
immune system may decline in tandem with cognitive function
during aging. However, it has been difﬁcult to draw conclusions
whether inﬂammation is a cause, a promoter, or simply a secondarynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic details and pathological features of the subjects
Group N Age Gender
(M%:F%)
Braak stageb MMSE CAMCOG
Control 20 79.2  3.3 35:65 1.72  0.32 28.8  0.8 na
PSNDa 21 85.0  1.0 57:43 2.48  0.25 27.2  0.4 89.7  1.3
PSDa 20 87.3  1.3 30:70 2.73  0.24 15.9  1.1 66.2  2.5
VaD 17 83.9  1.6 41:59 1.93  0.25 13.4  3.7 na
Mixed 18 84.5  1.2 44:56 5.13  0.22 10.6  2.36 na
AD 16 83.9  1.9 56:44 5.31  0.17 7.4  1.9 39.1  6.8
Numbers represent mean values (SEM) and for the given number (N) of subjects.
The causes of death included bronchopneumonia (95%), cardiac arrest, and carci-
noma with no particular distribution in any group. The time period of postmortem
interval between death and tissue retrieval ranged 39e47 hours for all the cases.
There were no differences in the length of postmortem delay between groups.
Key: AD, Alzheimer’s disease; CAMCOG, Cambridge cognition examination; F, fe-
male; M, male; MMSE, MinieMental State Examination; N, number; na, not avail-
able; NPD, no pathological diagnosis; PSD, poststroke demented; PSND, poststroke
nondemented; SEM, standard error of the mean; VaD, vascular dementia.
a Mean vascular pathology scores (range) for PSND and PSD groups were 13.5
(13e14) and 13.3 (9e17) compared to 8.1 (8e10) for controls (p < 0.05). These
scores were derived as described previously (Deramecourt et al., 2012).
b Braak staging scores were different in mixed and AD cases compared to all other
groups (p < 0.05).
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focused on Alzheimer’s disease (AD), as the most common form of
dementia, indicate a direct role for inﬂammatory and immune
processes in its pathogenesis (Rafnsson et al., 2007; Schmidt et al.,
2002; Schram et al., 2007; Sudduth et al., 2013; Weaver et al., 2002;
Whiteley et al., 2009). However, much less is known on the mod-
ulation of inﬂammatory responses in other dementias including
vascular or stroke-related dementias.
The inﬂammatory response of the body is a dynamic process,
and the proﬁle of cytokine responses may differ with the duration
and severity of an illness (Huberman et al., 1994, 1995; Jabbari Azad
et al., 2014). Cytokines in blood and cerebrospinal ﬂuid (CSF) have
been reported to be increased, decreased, or unaltered in AD,
vascular dementia (VaD), and ischemic stroke survivors (Alvarez
et al., 1996; Beridze et al., 2011; Narasimhalu et al., 2015; Schmidt
et al., 2002; Singh and Guthikonda, 1997; Sun et al., 2009;
Whiteley et al., 2012). Few population-based studies have shown
that high levels of interleukin (IL) IL-6, IL-8, and C-reactive protein
(CRP) are associated with poor cognitive status, including poor
performance in memory and processing speed, as well as cognitive
decline (Baune et al., 2008; Gimeno et al., 2008;Weaver et al., 2002;
Wright et al., 2006). In ischemic stroke, higher serum ILs were
associated with baseline cognitive impairment (IL-8) and subse-
quent cognitive decline (IL-12) (Narasimhalu et al., 2015). Clinical
trials have generally failed to demonstrate a robust beneﬁcial effect
of anti-inﬂammatory drugs in the progression of AD (Hoozemans
et al., 2011), implicating a complicated role of inﬂammation in the
pathogenesis. In contrast, although most trials were negative in
ischemic stroke injury, phase 2 trials with IL-1 receptor antagonist
and the board spectrum anti-inﬂammatory agent minocycline
demonstrated improved outcomes (Smith et al., 2015).
The immune system is also a key player in central nervous sys-
tem repair andmaintenance that undergoes a profound remodeling
process over the lifetime and has a major impact on individual’s
health and survival (Boraschi and Italiani, 2014; Fulop et al., 2010;
Grubeck-Loebenstein et al., 2009). Immunosenescence, or the ag-
ing immune system, is a constellation of age-related changes to the
immune system, resulting in greater susceptibility to infection and
reduced responses to infectious pathogen(s). The characteristics of
immunosenescence include age-induced thymic atrophy, bone
marrow decreased hematopoietic compartment, and increased
peripheral suppressor cell activity. It affects both innate and adap-
tive immune systems (Grubeck-Loebenstein et al., 2009).
Our aim was to investigate inﬂammatory cytokine proﬁles in
extracts of postmortem brain tissues from subjects with different
dementias usingmultiplex immunoarrays. In addition to poststroke
demented (PSD) and poststroke nondemented (PSND) subjects, we
assessed brains from prospectively assessed dementia subjects
diagnosed with VaD, mixed dementia, and AD and from age-
matched controls. With emphasis on PSD, we tested the hypothe-
sis that different dementias have distinct proﬁles of cytokines
compared to those without dementia.
2. Methods
2.1. Subjects
Brain tissues from a total of 112 subjects, including 21 PSND
and 20 PSD, 17 VaD, 18 mixed dementia, and 16 AD, were obtained
from the Newcastle Brain Tissue Resource, Newcastle University.
In addition, we analyzed brain tissue from similar age controls
(Table 1). For the poststroke subjects, ﬁnal MinieMental State
Examination (MMSE) and the highest and last revised Cambridge
Cognition Examination (CAMCOG) battery scores of the relevant
subjects were used to determine the cognitive proﬁle of analyzedsubjects. Thus, stroke survivors who did not meet DSM-IIIR or IV
criteria for dementia and had MMSE scores >25 and CAMCOG
scores >85 were designated as poststroke survivors with no de-
mentia. In most cases, bronchopneumonia was recorded as the
cause of death.
Neuropathological assessment was carried out as described
previously, using standardized protocols (Allan et al., 2011; Ihara
et al., 2010; Kalaria et al., 2004). Macroscopical infarcts, detected
by visual inspection while dissecting the brain, were subsequently
conﬁrmed by light microscopy. Hematoxylin-eosin staining was
used for assessment of structural integrity and infarcts, Nissl and
luxol fast blue staining for cellular patterns and myelin loss, Biel-
schowsky’s silver impregnation and amyloid b for CERAD and/or
Thal rating of neuritic plaques, Gallays for neuritic pathology, and
tau immunohistochemistry for Braak staging of neuroﬁbrillary
tangles. Vascular pathology scores were determined in PSND and
PSD cases and controls as described previously (Deramecourt et al.,
2012).
Pathological diagnosis of AD was consistent with the National
Institute on AgingeAlzheimer’s Association guidelines for the
neuropathological assessment of AD (Montine et al., 2012). VaDwas
diagnosed as described previously (Kalaria et al., 2004). In PSD
cases, a deﬁnite diagnosis of VaD was made when there were
multiple or cystic infarcts, lacunae, microinfarcts and small vessel
disease, and Braak stage IV in the presence of clinically overt
cognitive impairment (Deramecourt et al., 2012; Kalaria et al.,
2004). Mixed dementia was classiﬁed when there was signiﬁcant
vascular pathology and sufﬁcient degree of pathology to reach
Braak VeVI, in the presence of clinically veriﬁed dementia syn-
drome. Tissues from control subjects had occasional aging-related
pathology and were classiﬁed having “no pathological diagnosis”
(Table 1). However, they had no strokes, transient ischemic attacks
(excluded because of hypertension or cardiovascular risk factors), or
any type of dementing illness.2.2. Preparation of samples
One hundred to 150 mg frozen brain tissues from 5 different
brain regions namely, BA9 for frontal gray matter (FGM), BA21 for
temporal gray matter (TGM), the underlying frontal white matter
(FWM), and temporal white matter (TWM), as well as hippocampus
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tissues were homogenized in ice-cooled lysis buffer (3 mL per mg of
tissue wet weight, 50 mM Tris-Buffer, 150 mM NaCl, 0.05% Tween-
20, pH ¼ 7.5) with 2 phosphostease inhibitor (78,420, Thermo
Scientiﬁc) and Protease inhibitor cocktail (87,786, Thermo Scienti-
ﬁc) using the Precellys 24 tissue homogenizer (Bertin Technologies)
with 3 cycles of 20 seconds over 5 minutes interval). The homog-
enates were centrifuged at 10,000 rpm for 60 minutes at 4 C. The
supernatant was then collected and transferred immediately into 3
microtubes to avoid repeated freeze and thaw cycle: one 150 mL of
sample was kept at 80 C for multiplex array, one 20 mL of sample
was kept at 20 C for protein assay, and the rest of the sample was
stored at 80 C for future use. Protein concentrations were esti-
mated with the DC kit (500-0112, Bio-Rad).
2.3. Multiplex arrays
On the day of assays, protein homogenates were thawed on ice.
We assessed 37 cytokines in each sample with the Neuro-
inﬂammation Panel 1 (human) kit (Meso-Scale Discovery,
K15210D). Duplicate aliquots of 150 mL of 4 mg/mL samples in lysis
buffer containing 1% blocker A and 1 phosphatase and protease
inhibitor were prepared in a 96-well preparation plate. There were
5 mini plates for each Neuroinﬂammation Panel 1 (human) kit, and
eachmini plate was designed for the measurement of each group of
cytokines, up to 9 cytokines in each panel (Table 2). Calibrator di-
lutions and samples were prepared according to themanufacturer’s
recommendation (Table 2). The protocol for cytokine measurement
is summarized in Fig. 1. Cytokine concentrations were read in the
MESO QUICKPLEX SQ 120 from MSD with software DISCOVERY
WORKBENCH 4.0. For those analytes below the lower limit of
detection (LLOD, a calculated concentration corresponding to the
signal 2.5 standard deviations above the background [zero cali-
brator]) and those with no-reading, the LLOD were used for indi-
vidual samples and cytokines. The highest concentration at which
the coefﬁcient of variation (CV) of the calculated concentration
(ULOQ) was <20%, and the recovery of each calibrator was within
80%e120% of the known value. The lowest concentration at which
the CV of the calculated concentration (LLOQ) was <20%, and the
recovery of each calibrator was within 80%e120% of the known
value. The quantitative range of the assay lay between the lower
limit (LLOQ) and upper limit (ULOQ) values.
2.4. Statistical analysis
Statistical analysis was carried out using SPSS, version 21, with
the level of signiﬁcance set at p < 0.05. The demographics of the
samples including age, postmortem delay (PMD), were comparedTable 2
Reagents and sample preparation of Neuroﬂammation Panel 1 (human) kit from MSD m
MSD panel kits Analysts
Pronﬂammatory panel 1 IFN-g, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, TNF-a
Cytokine panel 1 IL-1a, IL-5, IL-7, IL-12p40, IL-15, IL-16, IL-17A, TNF-b, VEGF
Chemokine panel 1 Eotaxin, MIP-1b, Eotaxin-3, TARC, IP-10, MIP-1a, MCP-1, M
Angiogenesis panel 1 VEGF-C, VEGF-D, Tie-2, Flt-1, PIGF
Vascular injury panel 1 SAA, CRP, VCAM-1, ICAM-1a
Human bFGF Kit V-PLEX bFGFb
Key: CRP, C-reactive protein; FGF, ﬁbroblast growth factor; Flt-1, also known as VEGF-1
interferon-inducible protein; MCP, monocyte chemoattractant protein; MDC, macrophage
factor; SAA, serum amyloid A; TARC, thymus and activation-regulated chemokine; TN
endothelial growth factor.
a For vascular injury, prepare 50 mL (40 mL of diluent 101 and 10 mL of normalized sam
b The concentration of bFGFwas extremely high in the all brain tissue. A single human b
lysis buffer and then diluted 1:2 with Diluent 7.with theMann-Whitney U test. Therewere no statistical differences
between the groups. Because these cytokine measurements are
from different patients and different areas with multiple factors
involved, it is inadequate to analyze them with common nonpara-
metric tests (e.g., Mann-Whitney U test), as they are unable to
examine interaction effects. As such, raw data frommultiplex array
were ranked with aligned ranking transfer (Higgins and Tashtoush,
1994) (ARTool, http://depts.washington.edu/aimgroup/proj/art/),
and the ranking was analyzed with one-way analysis of variance
and Fisher’s LSD post hoc tests (>3 groups) or independent sample t
test (2 groups) for samples from all 5 areas and individual area. The
data were analyzed for the differences between the different
patient groups from all 5 areas and from individual area. They were
compared between different areas as well to see the area effects.
Homogenate measurements were presented as pg/mg of total
protein.
3. Results
The LLODs from our experiment were within the LLOD range in
the data sheet for almost all individual cytokines, except
macrophage-derived chemokine, macrophage inﬂammatory pro-
tein (MIP)-1b, and vascular endothelial growth factor (VEGF)-C
(Table 2 for abbreviations). Most recovery for each calibrator was
within 80%e120% of the known value (data not shown). We noted
predominantly similar concentration proﬁles of various cytokines
when plotted as demented and nondemented groups or as PSD and
PSND groups (Fig. 2A and B). The highest concentrations of the
analytes were of CRP and SAA (1e150 ng/mg), whereas several of
the key ILs were in low concentrations (1e10 pg/mg).
Because Extaxin, interferon (IFN)-gamma, IL-2, IL-5, IL-10, IL-
12p40, IL-17A, monocyte chemoattractant proteine4, macrophage-
derived chemokine, MIP-1 alpha, MIP-1 beta, TARC, TNF-alpha, and
TNF-beta were undetectable or close to LLOD, and not in the quan-
titative range of the assay between LLOQ and ULOQ, we did not take
these analyses further. We also found that IL-4, IL-13, Eotaxin-3, and
VEGF needed to be interpreted carefully because most of the mea-
surements were close to or just below LLOQ. For Tie 2, VEGF-C, and
VEGF-D, the measurements from FWMwere within the quantitative
range of the assay, whereas some measurements from the other
regions were near the LLOD. We therefore concentrated on the
following predominantly proinﬂammatory cytokines: basic ﬁbro-
blast growth factor (bFGF), CRP, fms-related tyrosine kinase 1, IL-1a,
IL-1b, IL-6, IL-7, IL-8, IL-15, IL-16, ICAM-1, interferon-inducible
proteine10, monocyte chemoattractant proteine1, placenta
growth factor, SAA, and VCAM-1. Most of the assay values for these
lay in the quantitative range of the assay and considered reliable. The
median and 5%e95% range of concentrations of these measurableultispot assay system
Diluent for
sample
and calibrator
Dilution Added volume
for diluent (mL)
Sample
(mL)
Diluent for
detection
antibody
Diluent 2 1:2 25 25 Diluent 3
Diluent 43 1:2 25 25 Diluent 3
DC, MCP-4 Diluent 43 1:4 37 13 Diluent 3
Diluent 7 1:2 25 25 Diluent 11
Diluent 101 1:5 20 5 Diluent 101
Diluent 7 1:2 25 25 Diluent 11
receptor; ICAM, intercellular adhesion molecule; IFN, interferon; IL, interleukin; IP,
-derived chemokine; MIP, macrophage inﬂammatory protein; PIGF, placenta growth
F, tumor necrosis factor; VCAM, vascular cell adhesion molecule; VEGF, vascular
ple) in the transfer plate and add 25 mL into the kit plate.
FGF kit had to be used for this speciﬁc cytokine, and samples were diluted 1:100with
Fig. 1. Flowchart of brain tissue preparation and analysis.
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observed wide variations, but the FWM often exhibited higher
concentrations of some of the cytokines, particularly vascular
growth related factors (not shown) and CRP.
3.1. Proinﬂammatory cytokines in dementia
When samples were designated into the demented group,
which included VaD, mixed, AD and PSD, and the non-demented
group, which included normal controls and PSND, we noted
signiﬁcantly lower concentrations of cytokines overall in demented
subjects (Table 3): IL-1 beta (p ¼ 0.000), IL-6 (p ¼ 0.000), IL-7 (p ¼
0.000), IL-8 (p ¼ 0.000), IL-16 (p ¼ 0.001), interferon-inducible
proteine10 (0.044), SAA (p ¼ 0.011), and IL-1 alpha (p ¼ 0.084).
However, compared to nondemented subjects, there were higherconcentrations of the following analytes in dementia: bFGF (p ¼
0.002), ICAM-1 (p ¼ 0.001), VEGF-C (p ¼ 0.000), VEGF-D (p ¼
0.000). More interestingly, when all the samples for all brain re-
gions from poststroke subjects were analyzed, relative to PSND
subjects, PSD had lower concentrations of IL-6 (p ¼ 0.000) and IL-8
(p ¼ 0.000). In contrast, there were higher concentrations of IL-1
alpha (p ¼ 0.040) in PSD compared to PSND subjects.
3.2. IL-6, IL-8, and CRP
IL-6 and IL-8 were analyzed further to explore speciﬁcity for
dementia types and regional differences based on the aforemen-
tioned ﬁndings. We reasoned that the concentrations of these cy-
tokines and CRPmight distinguish the demented and nondemented
subjects, and in particular PSD and PSND groups (Fig. 3 and Table 4).
Fig. 2. (A and B) Distribution of brain analytes in demented and control subjects. The analytes for all samples are grouped from the highest to the lowest concentrations. Red
symbols represent demented samples, and blue symbols represent nondemented sample. *Most of the measurements are undetectable or close to LLOD. **All measurements from
FWM are all in the quantitative range of the assay, and some of the measurements from all other areas are near to LLOD. ***Most of the measurements were close to LLOQ, and some
of the measurements were marginally below the LLOQ. For interpretation of the analyte abbreviations, see Table 2. (B) Brain analytes in poststroke demented (PSD) and non-
demented (PSND) subjects.
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groups with or without stroke (Fig. 3C). Statistical analysis by one-
way analysis of variance after Aligned Rank Transform (ART)
showed that the normal controls had signiﬁcantly higher levels of
IL6 and IL-8 than the disease groups, including PSND, PSD, VaD, AD,
and mixed, both when brain areas were analyzed separately, or
grouped (p < 0.01). To exclude all possible stroke-induced in-
ﬂuences (i.e., PSND and PSD subjects), only nonstroke samples were
analyzed with independent sample t test after ART. It was found
that nondemented samples (only controls without stroke) had
higher levels of IL-6 (p¼ 0.000) and IL-8 (p¼ 0.000) than the entire
sample of demented subjects (including AD, mixed dementia, and
VaD). Moreover, the normal controls had signiﬁcantly higher levels
of IL-6 and IL-8 compared to AD ormixed dementia or VaD (p< 0.02
for all; data not shown).
Between each disease group, statistical analysis showed that
controls had higher concentrations of IL-6 than all other groups (p <
0.001, Supplementary Table 1). The PSND group also showed higher
levels of IL-6 than PSD, VaD, and mixed dementia subjects, but
not different from AD (Fig. 3G). Control and PSND subjects also
had signiﬁcantly higher concentrations of IL-8 than PSD, VaD, and
mixed dementia groups, whereas no differences were apparent be-
tween control and PSND subjects (Supplementary Table 1, Fig. 3H).
Although AD subjects showed signiﬁcantly lower concentrations of
IL-8 than controls, there was no difference with the PSND group.
There were also no differences in the concentrations of both IL-6 and
IL-8 between PSD, VaD, and mixed dementia; however, there wasa difference between AD and PSD for IL-6 (p ¼ 0.006) and a trend
in IL-8 (p ¼ 0.061). When analysis was limited to comparison of
AD and normal controls, independent sample t tests (after ART)
showed that AD subjects exhibited lower concentrations of both
IL-6 (p ¼ 0.001) and IL-8 (p ¼ 0.019) compared to controls.
The concentrations of IL-6 were similar between the different
brain areas analyzed, with exception of the TWM, which had
signiﬁcantly lower IL-6 in relation to FGM, TGM, and hippocampus
(Hipp) (Fig. 3D). The white matter IL-8 content (both FWM and
TWM) was signiﬁcantly lower to that found in the gray matter
(FGM, TGM, and Hipp). There were no differences found between
FGM, TGM, and Hipp or between FWM and TWM (Fig. 3E). We also
noted signiﬁcant (p < 0.05) correlations between IL-6 and IL-8
concentrations and the MMSE and CAMCOG scores across all de-
mentias and in all poststroke subjects (Supplementary Table 2).
CRP was not signiﬁcantly altered between demented and non-
demented groups (p ¼ 0.257), or between PSD and PSND subjects
(p ¼ 0.50). However, CRP was signiﬁcantly higher in PSD compared
to VaD, mixed, AD, and control (Fig. 3L). The FWM had signiﬁcantly
lower levels of CRP than all the other brain areas (Fig. 3F).
4. Discussion
Our report represents the ﬁrst multiplex analyte assay in a large
number of postmortem brain tissues from different dementias. The
speciﬁcity of our results was demonstrated not only by the quan-
titative analyte changes but also by the varied regional distribution
Table 3
Themedian and 5%e95% range of measurements (pg/mg of total protein) for the detectable cytokines in PSND, PSD, nondemented (including control and PSND), and demented
(including PSD, VaD, mixed dementia, and AD)
Median (5%e95%) Nondemented Demented PSND PSD
Proinﬂammatory panel 1
IL-1b 0.77 (0.25e2.82) 0.63 (0.21e2.11) 0.77 (0.29e2.39) 0.73 (0.23e2.71)
IL-4 0.09 (0.03e0.41) 0.08 (0.02e0.36) 0.09 (0.02e0.33) 0.09 (0.02e0.37)
IL-6 0.84 (0.13e8.75) 0.42 (0.10e3.19) 0.69 (0.09e7.68) 0.39 (0.10e1.39)
IL-8 8.47 (1.79e81.58) 4.92 (1.75e27.71) 6.11 (1.51e116.09) 4.67 (2.21e17.96)
IL-13 0.66 (0.27e1.24) 0.60 (0.20e0.99) 0.63 (0.25e1.37) 0.62 (0.23e0.94)
Cytokine panel 1
IL-1a 3.75 (1.29e9.50) 3.32 (1.25e8.99) 3.62 (1.39e9.47) 4.21 (1.34e10.61)
IL-7 1.02 (0.40e2.90) 0.85 (0.22e2.38) 1.08 (0.27e2.48) 0.88 (0.32e2.63)
IL-15 1.10 (0.51e2.14) 1.13 (0.49e2.24) 1.10 (0.54e2.28) 1.14 (0.46e2.13)
IL-16 551.34 (268.54e1032.67) 489.37 (157.19e939.47) 558.50 (277.44e1032.67) 512.03 (170.91e920.59)
VEGF 1.84 (0.37e4.99) 1.49 (0.26e3.52) 1.59 (0.29e4.68) 1.55 (0.42e3.54)
Chemokine panel 1
Eotaxin3 7.25 (0.54e63.90) 5.91 (0.76e50.47) 7.63 (1.70e56.63) 6.89 (1.03e48.29)
IP-10 10.20 (3.48e71.07) 8.88 (2.90e27.54) 9.11 (3.65e156.22) 8.49 (3.81e26.69)
MCP1 19.51 (6.63e312.18) 19.82 (6.83e101.38) 18.92 (8.21e397.51) 18.25 (7.35e77.46)
Angiogenesis panel 1
VEGF-C 60.68 (29.09e1144.00) 62.30 (32.57e1242.13) 64.12 (29.10e1163.87) 58.42 (29.09e1187.55)
VEGF-D 4.91 (2.07e78.97) 6.60 (2.19e86.86) 4.91 (2.46e86.14) 6.01 (2.30e75.22)
Tie-2 84.83 (30.06e410.65) 80.67 (26.35e420.77) 87.81 (34.49e434.40) 95.20 (36.54e420.15)
FLT-1 1327.51 (655.84e2475.34) 1338.74 (726.02e2409.87) 1369.08 (878.99e2475.82) 1304.33 (684.08e2261.78)
PIGF 4.89 (1.85e13.90) 5.56 (2.29e14.37) 5.36 (1.97e14.67) 5.12 (2.52e11.72)
bFGF 5737.0 (3165.4e10,483.7) 6142.0 (3468.6e12,547.3) 5960.3 (3417.2e10,889.5) 6281.8 (3701.5e13,014.6)
Vascular injury panel 1
SAA 4176.5 (628.7e58,673.4) 3871.6 (608.0e56,675.8) 5721.2 (1000.1e80,591.9) 4934.4 (1067.1e48,981.4)
CRP 39,603.0 (5883.4e96,862.0) 33,381.4 (4486.4e106511) 44,230.4 (3257.3e110510.6) 44,845.5 (11,561.2e110865.6)
VCAM-1 1619.7 (642.3e4879.7) 1694.3 (601.4e5555.9) 1767.9 (648.5e5435.9) 1442.3 (565.3e5720.9)
ICAM-1 1233.7 (468.0e2501.3) 1310.4 (617.8e3307.6) 1365.3 (670.0e2549.2) 1179.6 (684.6e2747.0)
Values in BOLD show signiﬁcant differences between demented and non-demented or PSD and PSND subjects.
Key: AD, Alzheimer’s disease; CRP, C-reactive protein; ICAM, intercellular adhesion molecule; IL, interleukin; IP, interferon-inducible protein; MCP, monocyte chemoattractant
protein; PIGF, placenta growth factor; PSD, poststroke demented; PSND, poststroke nondemented; SAA, serum amyloid A; VaD, vascular dementia; VCAM, vascular cell
adhesion molecule; VEGF, vascular endothelial growth factor.
Fig. 2. (continued).
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Fig. 3. Concentrations of IL-6, IL-8, and CRP in different dementias and brain regions. (A) Boxplots from different disease group in each brain region for IL-6 (a), IL-8 (b), and CRP (c).
Boxplots for all samples from different regions: IL-6 (d), IL-8 (e), CRP (f). (B) Boxplots from different areas in each disease group for IL-6 (g), IL-8 (h), and CRP (i). Boxplots for all
samples from different diseases: IL-6 (j), IL-8 (k), CRP (l). (C) Boxplots showing IL-6 (m), IL-8 (n), and CRP (o) concentrations for samples from all nondemented and demented
subjects and from PSND and PSD subjects. *p < 0.05, **p < 0.005, ***p < 0.001. Abbreviations: AD, Alzheimer’s disease; CRP, C-reactive protein; FGM, frontal gray matter; FWM,
frontal white matter; IL, interleukin; PSD, poststroke demented; PSND, poststroke nondemented; TGM, temporal gray matter; TWM, temporal white matter; VaD, vascular dementia.
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Fig. 3. (continued).
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A. Chen et al. / Neurobiology of Aging 38 (2016) 56e6764of several cytokines. Overall, we found decreases in many cytokines
within both the gray and white matter across all dementia sub-
types, suggesting inﬂammatory or immune factors are noteworthy
substrates contributing to the pathogenesis of dementia per sé,
irrespective of their underlying pathological changes.
We provide reliable estimates of individual cytokine concen-
trations in relation to brain protein in human brain tissues. They
range from very high concentrations, for example, CRP, SAA, and
bFGF to just barely detectable levels such as those of IFN-gamma,
TNF-alpha, and TNF-beta. Because the periods of PMD were com-
parable between the dementia groups and controls, we surmise
that postmortem alterations for any cytokine would be to a similar
degree across samples. Therefore, the relative changes we
observed between dementia samples and groups would be valid,
especially that the cytokine assays were performed on the same
occasion.
Most previous studies were performed in body ﬂuids, primarily
plasma (or sera) and CSF quantiﬁed as weight per unit volumes
(Brosseron et al., 2014; Hu et al., 2012; Lee et al., 2009; Swardfager
et al., 2010). Although it is not entirely adequate to compare cyto-
kine concentrations between brain tissues and those reported
previously in plasma and CSF samples, it may be of relevance here
to consider the often studied cytokines such as IL-6 and IL-8. In a
recent study (Leung et al., 2013), the median (range) plasma con-
centrations of IL-6 and IL-8 in elderly controls were reported to be
8.9 (1.3e36.6) and 8.3 (1.9e31.3) pg/mL. With reference to the CSF,
the median concentrations of IL-6 and IL-8, in normal elderly sub-
jects in another study (Westhoff et al., 2013), were reported to beTable 4
Signiﬁcance by one-way ANOVA test after ART ranking for all samples from each
brain area and for all 5 brain areas of demented and nondemented subjects
Brain regions and test groups IL-6 IL-8
FGM Demented vs. nondemented 0.013 0.014
FWM Demented vs. nondemented 0.005 0.023
TGM Demented vs. nondemented 0.004 0.003
TWM Demented vs. nondemented 0.002 0.037
Hipp Demented vs. nondemented 0.017 0.026
All areas Demented vs. nondemented 0.000 0.000
Key: ANOVA, analysis of variance; FGM, frontal gray matter; FWM, frontal white
matter; TGM, temporal gray matter; TWM, temporal white matter.1.0 (0.2e2.2) and 28.4 (22.7e42.5) pg/mL, respectively. Given that
widely published values for total protein in 1 mL of plasma and
1mL CSF contain approximately 70 (60e80) and 0.45 (0.2e0.6) mg/
mL protein, respectively (Felgenhauer, 1974), the aforementioned
median (and range) concentrations of IL-6 in plasma reported by
Leung et al. (2013) calculate to 0.13 (0.02e0.52) pg/mg protein,
whereas that in CSF reported by Westhoff et al. (2013) calculate to
2.2 (0.44e4.9) pg/mg protein. Similarly, for IL-8, normal elderly
plasma contains approximately 0.12 (0.03e0.45) pg/mg protein and
CSF approximates to 63.1 (50.5e94.4) pg/mg protein. The values for
CSF of 1.7 (0.7e14.8) and 34.9 (17.5e64.2) pg/mL for these cytokines
reported by Kern et al. (2014) also fall within a comparable range.
These calculations indicate that compared to plasma, CSF has
greater amounts of both IL-6 and IL-8, and there is a 20-25 fold
difference between these cytokines in the CSF but almost similar
amounts in the plasma. Although we found a >7-fold difference in
concentrations of these 2 cytokines within the brain, we report
generally lower concentrations of IL-8 per mg protein, in particular,
compared to the recently published CSF concentrations (Kern et al.,
2014; Westhoff et al., 2013). The highest brain values of IL-6 and IL-
8 were determined to be 8.9 and 40.0 pg/mg protein, respectively.
Various factors could contribute to these differences. Because the
total CSF protein in older (>70 years) than younger people
(0.2e0.6 mg/mL) is generally greater, we suggest the mean con-
centrations we recorded in brain are realistic.
We speciﬁcally noted decreased concentrations of both IL-6 and
IL-8 in brain tissues of demented subjects. As PSD and PSND sub-
jects in our cohort had similar survival periods after stroke and
exhibited comparable degrees of vascular burden (Allan et al.,
2011), the lower production of IL-6 and IL-8 in PSD suggests a
speciﬁc change related to a factor(s) which contribute to dementia
per sé. When samples from stroke patients (PSND and PSD) were
excluded from the cohort, all other forms of dementia also showed
signiﬁcantly lower levels of IL-6 and IL-8 than the normal controls,
implying a possible similar diminished immune response in the
context of dementia including AD. The origin of IL-6 in the brain is
uncertain, with a number of studies hinting that neurons, glial cells,
and the vascular endothelium could be the source of IL-6 (Jang et al.,
2008; Suzuki et al., 2009). Indeed, immunostaining with IL-6
antibody was found within neuronal and glial cells in formalin
ﬁxed brain tissue sections (AC and RNK, data not shown). Although
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pleiotrophic effects (Frei et al., 1989). IL-6 was also shown to be
essential for poststroke angiogenesis (Gertz et al., 2012) and a
protectant of cerebral infarction (Herrmann et al., 2003; Loddick
et al., 1998). IL-6 elevation in CSF of stroke patients and its further
correlationwith stroke severity have been reported in some studies
(Beridze et al., 2011; Vila et al., 2000) although Sun et al. (2009) did
not ﬁnd any change in IL-6 in the CSF. Plasma elevated concentra-
tions of IL-6, IL-1 beta, and TNF-alpha have also been reported in
the elderly (Kern et al., 2014). Although this seems to contradict the
expected functional defects, chronic subclinical inﬂammation may
be caused by partial inability of the aged immune system to elim-
inate certain pathogens, such as products of degradation processes
implicating an inefﬁcient immune response in the elderly.
Our results are consistent with some previous ﬁndings, report-
ing decreases in IL-6 in the brain tissues from the frontal gray and
white matter of VaD andmixed dementia in comparison to controls
(Mulugeta et al., 2008). Kim et al. (2011) reported signiﬁcantly
lower plasma IL-8 levels in subjects with mild cognitive impair-
ment and AD than controls. Similar ﬁndings of signiﬁcant decreases
in TNF-alpha and IL-6 in CSF and serum, respectively, were reported
in AD subjects with a mean duration of dementia for 2.5 years
(1.5e3.4 years) (Richartz et al., 2005). Yamada et al. (1995) also
reported decreased CSF IL-6 in AD, with the magnitude of CSF IL-6
reduction signiﬁcantly greater in early onset dementia. However,
serum concentrations of some proteins may increase initially but
decline in later M2 stages of disease like AD, as elegantly demon-
strated by Sudduth et al. (2013). In our cohort, most AD patients had
severe degree of dementia, with MMSE score lower than 8, which
may indicate that they are more fragile and exhibit more intense
immunosenesence.
In AD, higher levels of cytokines (IL-6 and IFN-gamma) were
reported in lymphocytes, and these were related to more advanced
age (Jabbari Azad et al., 2014). Similarly, in another study (Licastro
et al., 2000), higher concentrations of IL-6 in peripheral blood of
AD subjects were reported, but this was not evident in the CSF
(Engelborghs et al., 1999). Baune et al. (2008) reported that
increased serum concentrations of IL-8 were associated with poor
cognitive performance on cognitive tests in healthy elderly in-
dividuals. These inconsistent ﬁndings in the context of our ﬁndings
in postmortem brain tissue may be attributed to differences in
study populations, for example, inclusion criteria of subjects
(different degrees of pathogenesis), sample size, and different
protocols for sample type and preparation and variability in assay
procedures. For most of the studies, cytokines were sampled from
peripheral blood (serum, plasma, or whole blood cells) or CSF and
often have short half-lives. Theymay reach higher concentrations at
or near sites of release and much lower concentrations after dilu-
tion into blood and CSF.
Remarkably, when whole blood supernatants were stimulated
by lipopolysaccharide (bacterial virulence factors that induce
inﬂammation), there was a diminished production of proin-
ﬂammatory cytokines (TNF-a and IL-1b) in older people compared
to younger individuals (Bruunsgaard et al., 1999). This lack of
response in cytokine production on stimulation reﬂects the general
dysfunction of particular immune cells on inﬂammatory stimuli,
indicating the presence of immunosenescence, with an attenuated
secretory activity for IL-6, IL-12, IFN-gamma, TNF-alpha of mono-
cytes and/or macrophages within whole blood cell cultures of AD
subjects. This suggests a systemic, possibly age-related alteration of
immune mechanisms involved in AD pathogenesis (Richartz et al.,
2005). De Luigi et al. (2002) found that dementia patients exhibi-
ted an upregulation of circulating cytokines and a downregulation
of cytokines released by blood cells after exposure to lipopolysac-
charide, suggesting a similar mechanism is present in both AD andmulti-infarct dementia. In addition, there is further evidence of
premature immunosenescence with decreased T- and B-cell
numbers and insufﬁcient microglial phagocytosis in AD subjects
(Richartz-Salzburger et al., 2007). Thus, better cognitive perfor-
mancewas associatedwith less effectormemory CD4þ Tcells, more
naïve CD8þ T cells, and more B cells in healthy elderly people. In
contrast, signiﬁcantly lower levels of CD4þ naïve T cells and an
increase in the ratio of the activated and/or naïve CD4þ T cells were
found in AD subjects (Tan et al., 2002). It is not unlikely there are
shared pathways leading to cognitive dysfunction among various
types of dementia. Immunosenescence could be one possible cause,
promoter, or result of dementia pathology. Alternatively, they occur
simultaneously and are interrelated and interact with each other
(De Luigi et al., 2002).
The dampening of the inﬂammatory and/or immune responses
in relation to pathological changes may not only occur in AD, but
also in other types of dementias, such as VaD and PSD as evident
from our study. This phenomenon has been linked to other dis-
eases. For example, the percentages of CD8þ naïve and CD8þ recent
thymic emigrant cells, and T-cell receptor rearrangement excision
circle levels in peripheral blood cells were signiﬁcantly lower in
cancer patients than in age-matched controls (Falci et al., 2013).
Cancer patients also have signiﬁcant shorter telomere lengths and
signiﬁcant lower level of CRP and IL-6 and nutritional markers in
their peripheral blood samples, when compared to the controls
(Falci et al., 2013). It is plausible that subjects destined to develop
dementia have a diminished inﬂammatory response, encompassing
immunosenescence. These subjects who are generally frail develop
greater susceptibility to infection but reduced responses and
impaired elimination of pathogens (Boraschi and Italiani, 2014;
Grubeck-Loebenstein et al., 2009). Although more evidence needs
to be gathered to demonstrate that immunosenescence causes
dementia, studies using strategies to rejuvenate the immune sys-
tem partially have demonstrated memory recovery in immune-
deﬁcient mice (Ron-Harel et al., 2008).
There are some limitations to our study. It is possible that the
long postmortem interval could have contributed to related global
or differential changes in cytokines. The cause of death and ante-
mortem status including any comorbidities could be additional
factors inﬂuencing the observed results. The main cause of death
in our sample was bronchopneumonia (Allan et al., 2011). How-
ever, there was also no correlation between cytokine levels
and PMD, as indicated by multiple regression analysis, and
there were no differences in PMD between the groups. We also
could not delineate any of the groups from controls based on any
known antemortem comorbidities. We would expect all brain re-
gions to have been affected equally, but clearly, there were dif-
ferential responses in cytokines. Another factor is that prior
medications could have modulated the cerebral expression of cy-
tokines. However, as previously reported, all subjects had similar
use of medication in respect to their mental and physical health
(Allan et al., 2011).
Our study provides strong evidence of impaired inﬂammatory
mechanisms in the pathogenesis of dementia. It is possible that
the decreased inﬂammatory response reﬂects cellular changes in
reactive cells or simply global brain atrophy related to dementia.
Further assessment of cell speciﬁc markers of microglia and
astrocyte markers could demonstrate whether there are any
changes in reactive cells and whether the decreased cytokine
levels were because of dampened cellular responses. The inves-
tigation of inﬂammatory markers in bloods from the same cohort
may be of further use. Better understanding of the association
between the immune system and cognitive function will help us
to develop new strategies to counter against cognitive
dysfunction.
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